Journal of Stroke & Cerebrovascular Diseases
Volume 16, Issue 4 , Pages 173-179 , July 2007

The PAI-1 4G/5G Gene Polymorphism and Ischemic Stroke: An Association Study and Meta-Analysis

  • John Attia, MD, PhD, FRCPC, FRACP

      Affiliations

    • Centre for Clinical Epidemiology & Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle NSW Australia
    • Department of Medicine, John Hunter Hospital, New Lambton, NSW Australia
    • Corresponding Author InformationAddress reprint requests to John Attia, MD, PhD, FRCPC, FRACP, Department of Medicine, John Hunter Hospital, Locked Bag 1, Hunter Region Mail Centre, Newcastle, NSW 2310, Australia.
    • ,
  • Ammarin Thakkinstian, PhD

      Affiliations

    • Centre for Clinical Epidemiology & Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle NSW Australia
    • ,
  • Yang Wang, MB, PhD

      Affiliations

    • Stroke Service, Department of Neurology, John Hunter Hospital, New Lambton, NSW Australia
    • ,
  • Lisa Lincz, PhD

      Affiliations

    • Hunter Haematology Research Group, Newcastle Mater Misericordiae Hospital, Waratah, NSW Australia
    • ,
  • Mark Parsons, MBBS, PhD, FRACP

      Affiliations

    • Stroke Service, Department of Neurology, John Hunter Hospital, New Lambton, NSW Australia
    • ,
  • Jonathan Sturm, MBBS, PhD, FRACP

      Affiliations

    • Neurosciences Department, Gosford Hospital, Gosford, NSW Australia
    • ,
  • Patricia McGettigan, BSc(Pharm), MD, FRCPI, FRACP

      Affiliations

    • Department of Medicine, Newcastle Mater Misericordiae Hospital, Waratah, NSW Australia
    • ,
  • Rodney Scott, PhD, PD, FRCPath, FHGSA

      Affiliations

    • Hunter Area Pathology Service, John Hunter Hospital, New Lambton, NSW Australia and Discipline of Medical Genetics, University of Newcastle, Newcastle NSW Australia.
    • ,
  • Cliff Meldrum, PhD, MHGSA

      Affiliations

    • Hunter Area Pathology Service, John Hunter Hospital, New Lambton, NSW Australia and Discipline of Medical Genetics, University of Newcastle, Newcastle NSW Australia.
    • ,
  • Christopher Levi, MBBS, FRACP

      Affiliations

    • Stroke Service, Department of Neurology, John Hunter Hospital, New Lambton, NSW Australia

Received 22 December 2006 ,Accepted 14 March 2007.

References 

  1. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis. 1991;5:197–206
  2. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739–10745
  3. Eriksson P, Kallin B, Hooft F, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci. 1995;92:1851–1855
  4. Festa A, D’Agostino R, Rich SS, et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: The Insulin Resistance Atherosclerosis Study. Circulation. 2003;107:2422–2427
  5. Panahloo A, Mohamed-Ali V, Lane A, et al. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes. 1995;44:37–42
  6. Roest M, Banga JD. Editorial comment: Genetic make-up for increased PAI-1 expression protects against stroke. Stroke. 2003;34:2828–2829
  7. Boekholdt SM, Bijsterveld NR, Moons AHM, et al. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: A systematic review. Circulation. 2001;104:3063–3068
  8. Wiklund P-G, Nilsson L, Ardnor SN, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: Replicated findings in two nested case-control studies based on independent cohorts. Stroke. 2005;36:1661–1665
  9. Bang CO, Park HK, Ahn MY, et al. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis. 2001;11:294–299
  10. Crainich P, Jenny NS, Tang Z, et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promotor polymorphism with cardiovascular disease in the elderly. J Thromb Haemost. 2003;1:1799–1804
  11. Jood K, Ladenvall P, Tjärnlund-Wolf A, et al. Fibrinolytic gene polymorphism and ischemic sroke. Stroke. 2005;36:2077–2081
  12. Hindorff LA, Schwartz SM, Siscovick DS, et al. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk. 2002;9:131–137
  13. van Goor ML, Garcia EG, Leebeek F, et al. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke: A case-control study. Thromb Haemost. 2005;93:92–96
  14. Catto AJ, Carter AM, Stickland M, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost. 1997;77:730–734
  15. Chen CH, Eng HL, Chang CJ, et al. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J Lab Clin Med. 2003;142:100–105
  16. Hoekstra T, Geleijnse JM, Kluft C, et al. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke. 2003;34:2822–2828
  17. Petrovic D, Milananez T, Kobal J, et al. Prothrombotic gene polymorphisms and atherrombotic cerebral infarction. Acta Neurol Scand. 2003;108:109–113
  18. Endler G, Lalouschek W, Exner M, et al. The 4G/4G genotype at nucleotide position −675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol. 2000;110:469–471
  19. Kain K, Young J, Bamford J, et al. Determinants of plasminogen activator inhibitor-1 in South Asians with ischaemic stroke. Cerebrovasc Dis. 2002;14:77–83
  20. Ladenvall P, Wall U, Jern S, et al. Identification of eight novel single-nucleotide polymorphisms at human tissue-type plasminogen activator (t-PA) locus: Association with vascular t-PA release in vivo. Thromb Haemost. 2000;84:150–155
  21. Wolf AT, Medcalf RL, Jern C. The t-PA −7351C→T enhancer polymorphism decreases Sp1 and Sp3 protein binding affinity and transcriptional responsiveness to retinoic acid. Blood. 2005;105:1060–1067
  22. Ladenvall P, Johansson L, Jansson JH, et al. Tissue-type plasminogen activator −7351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost. 2002;87:105–109
  23. Jannes J, Hamilton-Bruce M, Pilotto L, et al. Tissue plasminogen activator −7351C/T enhancer polymorphism is a risk factor for lacunar stroke. Stroke. 2004;35:1090–1094
  24. Hatano S. Experience from a multicenter stroke register: A preliminary report. Bull World Health Organ. 1976;54:541
  25. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial (TOAST (Trial of Org 10172 in Acute Stroke Treatment)). Stroke. 1993;24:35–41
  26. Tirschwell DL, Longstreth WT, Becker KJ, et al. Shortening the NIH Stroke Scale for use in the prehospital setting. Stroke. 2002;33:2801–2806
  27. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke: Background and study protocol. Stroke. 1985;16:885–890
  28. Wang Y, Lim LL-Y, Levi C, et al. The influence of admission body temperature on stroke mortality. Stroke. 2000;31:404–409
  29. Weir CJ, Murray GD, Dyker AG, et al. Is hyperglycemia an independent predictor of poor outcome after acute stroke? (Results of a long-term follow-up study). BMJ. 1997;314:1303–1306
  30. Margaglione M, Grandone E, Cappucci G, et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost. 1997;77:605–606
  31. Cuzick J. Wilcoxon-type test for trend. Stat Med. 1985;4:87–90
  32. Mohr JP, Albers GW, Amarenco P, et al. Etiology of stroke. Stroke. 1997;28:1501–1506
  33. Catto AJ, Kohler HP, Bannan S, et al. Factor XIII Val 34 Leu: A novel association with primary intracerebral hemorrhage. Stroke. 1998;29:813–816
  34. Jood K, Ladenvall C, Resengren A, et al. Family history in ischemic stroke before 70 years of age. Stroke. 2005;36:1383–1387
  35. Zhan M, Zhou YL, Han ZC. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China. Chin Med J. 2003;116:1707–1717
  36. Ding Z, Pan J. Distribution of PAI-1 promoter 4G/5G polymorphism in healthy Chinese and functional characterization using a luciferase reporter vector. Ann Hematol. 2005;84:183–187
  37. Wong TYH, Poon P, Szeto CC, et al. Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int. 2005;57:632–638

 Supported by a research grant from the Hunter Medical Research Institute and the Australian National Heart Foundation. The authors have no conflicts of interest to declare.

PII: S1052-3057(07)00039-0

doi: 10.1016/j.jstrokecerebrovasdis.2007.03.002

Journal of Stroke & Cerebrovascular Diseases
Volume 16, Issue 4 , Pages 173-179 , July 2007

Article Tools

* Image Usage & Resolution